Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials

Fig. 2

Progression-free survival of patients with endometrial cancer treated with PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel chemotherapy-based versus carboplatin plus paclitaxel chemotherapy-based. dMMR/MSI-H, mismatch repair–deficient/microsatellite instability; pMMR/MMS, mismatch repair–proficient/mismatch repair

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us